Despite ongoing pressures in China, revenue and trading profit at the FTSE 100 firm rose 5.3% and 8.2% respectively in 2024.

The medical-technology company was boosted by its sports medicine segment and an improved trading margin.

The chief executive of medical device maker Smith & Nephew has rejected shareholder calls to break up the business, as the ...

Barclays analyst Hassan Al-Wakeel maintained a Hold rating on Smith & Nephew (SN – Research Report) today and set a price target of £11.70.

Canaccord Genuity Group reiterated their hold rating on shares of Smith & Nephew (NYSE:SNN – Free Report) in a research report report published on Wednesday morning,Benzinga reports. Canaccord Genuity ...

New York State Common Retirement Fund reduced its holdings in shares of Smith & Nephew plc (NYSE:SNN – Free Report) by 0.5% ...

Market darling Rolls Royce (RR) is going from strength to strength. After a return to dividends topped with a lucrative ...

Good morning, and welcome to the Smith & Nephew Q4 and full year 2024 Results Presentation. I’m Deepak Nath, I’m the Chief ...

Medical products maker Smith+Nephew's wound business will take a hit from U.S. tariffs on imports from China, as the British company has "significant" manufacturing in the Asian country for that ...

In a report released today, David Adlington from J.P. Morgan maintained a Buy rating on Smith & Nephew (SN – Research Report), with a price ...

Smith+Nephew reported higher revenue growth for 2024, as the company’s 12-Point Plan delivered growth and lower costs.

The medical technology giant, which is listed on the FTSE 100, has been in the midst of a turnaround effort, and recently ...